FULCFulcrum Therapeutics, Inc.

$411M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M+167.0% YoY

Gross Profit

-$12M-246.0% margin

Operating Income

-$21M-420.9% margin

Net Income

-$21M-419.8% margin

EPS (Diluted)

$-0.57

QoQ Revenue Growth

+12.6%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$256M

Total Liabilities

$25M

Stockholders' Equity

$231M

Cash & Equivalents

$65M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$2M	+167.0%
Gross Profit	-$12M	-$14M	+12.0%
Operating Income	-$21M	-$19M	-8.7%
Net Income	-$21M	-$19M	-9.3%

FULC Q3 2021 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena